PRO-PHARMACEUTICALS ANNOUNCES TWO INTERNATIONAL CLINICAL SITES IN COLORECTAL CANCER TRIAL

A A

Pro-Pharmaceuticals, Inc. (Amex: PRW), a developer of novel carbohydrate compounds that enable the targeted delivery of drugs, today announced the addition of two clinical sites in Israel: Shaare Zedek Medical Center in Jerusalem and Soroka Medical Center in Beer Sheva of its Phase II colorectal cancer trial with DAVANAT(R)/5-FU. Patients are now being recruited at six clinical sites, including four in the United States: Medical Oncology and Hematology, Waterbury, CT; Hematology-Oncology Associates of the Treasure Coast, Port St. Lucie, FL; Ochsner Clinic, New Orleans, LA, and University of Michigan Comprehensive Cancer Center, Ann Arbor, MI.

Genetic Engineering News

(http://www.genengnews.com/news/bnitem.aspx?name=1125165XSL_NEWSML_TO_NEWSML_WEB.xml)